Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 6—June 2012


Pretransplant Fecal Carriage of Extended-Spectrum β-Lactamase–producing Enterobacteriaceae and Infection after Liver Transplant, France

Frédéric BertComments to Author , Béatrice Larroque, Catherine Paugam-Burtz, Federica Dondero, François Durand, Estelle Marcon, Jacques Belghiti, Richard Moreau, and Marie-Hélène Nicolas-Chanoine
Author affiliations: Hôpital Beaujon, Clichy, France (F. Bert, B. Larroque, C. Paugam-Burtz, F. Dondero, F. Durand, E. Marcon, J. Belghiti, R. Moreau, M.H. Nicolas-Chanoine); Université Paris VII Faculté de Médecine D. Diderot, Paris, France (C. Paugam-Burtz, F. Durand, J. Belghiti, M.H. Nicolas-Chanoine); INSERM U 773 Centre de Recherche Biomédicale Bichat-Beaujon, CRB3, Paris (F. Durand, R. Moreau, M.H. Nicolas-Chanoine)

Main Article

Table 2

Temporal evolution of ESBLE pretransplant fecal carriage and posttransplant infection, France, by time period, January 2001–April 2010*

Variable No. (%) patients
p value†
2001–2003, n = 185 2004–2006, n = 196 2007–2008, n = 188 2009–2010, n = 141
Pretransplant ESBLE fecal carriage 0 5 (2.5) 9 (4.8) 15 (10.6) <0.0001
Posttransplant ESBLE infection 3 (1.6) 9 (4.6) 9 (4.8) 18 (12.8) <0.0001

*ESBLE, extended spectrum β-lactamase–producing Enterobacteriaceae.
†Comparison among the 4 periods by test of trend.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO